Medicenna Therapeutics Corp (MDNA.TO) has recently faced notable declines amid developments in its public offering.
This week, Medicenna has seen a significant drop in its stock price, reflecting broader concerns in the biotech sector and investor sentiment regarding its public offering activities.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeAdvertisement
Market cap
$37.38M
52W high
$1.97
52W low
$0.34
1W change
+6.58%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 690.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+690.1% Upside
Current Price
C$0.41
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
40.5%
Annualized
90-Day Vol
68.5%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.34
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.38 | C$0.33 – C$0.44 |
| 60 trading days | C$0.36 | C$0.30 – C$0.44 |
| 90 trading days | C$0.34 | C$0.27 – C$0.43 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the implications of Medicenna's recent public offering and its financial health, especially in light of its current stock performance and market conditions.
Medicenna's Stock Down 63.5% YTD Amid Public Offering Developments.
Despite raising $4.44 million through a public offering, the stock has struggled, closing at C$0.36, well below its 52-week high of C$1.97.
Bull case
Analysts remain optimistic about Medicenna, with an average target price significantly higher than current levels. This suggests there could be potential for recovery if the company achieves positive results in its clinical developments.
Bear case
However, the declining stock price, combined with a high beta and poor financial metrics, raises concerns about Medicenna's ability to attract investment and effectively execute its clinical programs.
Recent Price Action
Medicenna has had a tough week, with the stock down 1.35% today and 7.59% over the past week. Year-to-date, the stock has fallen 63.50%, closing at C$0.36. This decline is particularly significant when considering the company's 52-week range of C$0.36 to C$1.97.
Company Developments
Advertisement
While there hasn't been major news this week, Medicenna recently finalized the terms of a public offering, pricing units at $0.50 each. This offering raised approximately $4.44 million to support ongoing clinical programs. The market's reaction has been lukewarm, as reflected in the stock's performance.
Technical Picture
Technically, Medicenna's stock is currently trading below both its 50-day moving average (C$0.47) and its 200-day moving average (C$0.86), indicating a bearish trend. The stock's beta of 1.89 suggests it is more volatile than the broader market. Trading volume has also been low, with the latest volume at 18,000 shares, which is only 0.43 times the 20-day average of 78,820 shares.
Insider Activity
No recent insider activity has been reported, which may indicate a lack of confidence from company executives in the current stock valuation or future performance.
Price Action Summary
As of the latest close, Medicenna Therapeutics Corp (MDNA.TO) is priced at C$0.36, reflecting a 1D decline of 1.35%. Investors should remain cautious as the company navigates its financial and operational challenges.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
